Lumigan ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.

Lumigan - Pharmacology:

Lumigan is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Lumigan reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Lumigan is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. This decreases the pressure within the eye.

Lumigan mini report

Lumigan NDA
NDA - A product marketed under an approved New Drug Application
Start - Stop data
Start - Stop data
not occurred

Lumigan for patients

Patients should be informed that LUMIGAN™ has been reported to cause increased growth and darkening of eyelashes and darkening of the skin around the eye in some patients. These changes may be permanent.

Some patients may slowly develop darkening of the iris, which may be permanent.

When only one eye is treated, patients should be informed of the potential for a cosmetic difference between the eyes in eyelash length, darkness or thickness, and/or color changes of the eyelid skin or iris.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients should also be advised that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, they should immediately seek their physicians advice concerning the continued use of the multidose container.

Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physicians advice.

Contact lenses should be removed prior to instillation of LUMIGAN™ and may be reinserted 15 minutes following its administration. Patients should be advised that LUMIGAN™ contains benzalkonium chloride, which may be absorbed by soft contact lenses.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.

Lumigan Interactions

No Information Provided

Lumigan Contraindications

LUMIGAN™ (bimatoprost ophthalmic solution) 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.

Generic name, Overdose, Half Life Lumigan, Food Interactions, Chemical, etc..

Lumigan see also FDA report

Eye drop

Chemical structure:
O N O O O H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H C25H37NO4 2D chemical structure C25H37NO4 SVG | 2D structure Bimatoprost | Salmeterol | C25H37NO4 chemical names, chemical properties, classification C25H37NO4